PEPCK deficiency, mitochondrial
PEPCK Deficiency, Mitochondrial is a rare metabolic disorder characterized by a deficiency in the enzyme phosphoenolpyruvate carboxykinase (PEPCK). This enzyme plays a crucial role in gluconeogenesis, the process by which glucose is synthesized from non-carbohydrate sources. The mitochondrial form of PEPCK deficiency affects the enzyme located in the mitochondria, one of two forms of PEPCK found in humans. The disorder leads to various metabolic complications, including hypoglycemia, lactic acidosis, and failure to thrive.
Symptoms and Signs[edit | edit source]
Patients with mitochondrial PEPCK deficiency typically present with a range of symptoms that may include:
- Hypoglycemia (low blood sugar)
- Lactic acidosis (buildup of lactic acid in the body)
- Failure to thrive in infants
- Hepatomegaly (enlarged liver)
- Muscle weakness
- Developmental delay
Causes[edit | edit source]
Mitochondrial PEPCK deficiency is caused by mutations in the PEPCK-M gene, which encodes the mitochondrial form of the enzyme phosphoenolpyruvate carboxykinase. These genetic mutations lead to reduced activity or complete absence of the enzyme, disrupting normal gluconeogenesis and energy metabolism.
Diagnosis[edit | edit source]
Diagnosis of mitochondrial PEPCK deficiency involves a combination of clinical evaluation, laboratory testing, and genetic testing. Laboratory tests may show hypoglycemia, lactic acidosis, and elevated levels of certain amino acids in the blood. Genetic testing can confirm mutations in the PEPCK-M gene.
Treatment[edit | edit source]
There is no cure for mitochondrial PEPCK deficiency, and treatment focuses on managing symptoms and preventing metabolic crises. Treatment strategies may include:
- Dietary management to maintain normal blood glucose levels
- Supplements or medications to manage lactic acidosis
- Close monitoring of liver function and growth in children
Prognosis[edit | edit source]
The prognosis for individuals with mitochondrial PEPCK deficiency varies depending on the severity of the enzyme deficiency and the effectiveness of management strategies. Early diagnosis and intervention can improve outcomes.
See Also[edit | edit source]
This metabolic pathology related article is a stub. You can help WikiMD by expanding it.
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD